Eugeroic / wakefulness-promoting agent (R-enantiomer)

Plain-language summaryIntrigue 65 / 100

Armodafinil, sold as Nuvigil, is the active half of modafinil purified out as a single enantiomer. It produces longer-lasting wakefulness than racemic modafinil because it lacks the rapidly cleared inactive enantiomer. It is FDA-approved for the same indications as modafinil. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundFederally scheduled

42/100

Chiral-switch refinement of modafinil with better PK but no new research frontier

Look, armodafinil is modafinil with the (S)-enantiomer removed. That’s the whole story pharmacologically. The R-enantiomer carries most of the wakefulness-promoting activity in the racemate anyway, and isolating it gives you a flatter plasma curve and sustained alertness later into the day at lower per-milligram doses. That’s a real PK advantage. But from a research-novelty standpoint, its the same DAT-binding, orexin-downstream, histaminergic mechanism modafinil brought to the table decades ago. Nothing here has changed.

The chiral-switch strategy is a well-worn pharmaceutical move. Esomeprazole from omeprazole, escitalopram from citalopram. It reliably produces incremental improvements in a drug’s profile without generating new science. Armodafinil did exactly what it was designed to do: gave Cephalon a new patent clock on a compound approaching generic competition. For a bench scientist, that’s not interesting. The mechanism hasn’t moved. The biology is the same.

What we’d credit: the evidence base is genuinely solid. FDA approval in 2007 for narcolepsy, obstructive sleep apnea, and shift work sleep disorder required real RCT data, and multiple replicated trials show meaningful effect sizes in sleep-disordered populations. If you’re investigating wakefulness biology, DAT pharmacology, or orexin system interactions, armodafinil is a well-characterized probe with regulatory-grade human data behind it. Its cleaner PK relative to the racemate makes it a marginally more controlled tool if your program specifically requires modafinil-class eugeroics and you want to minimize the early (S)-enantiomer peak confound.

What we don’t like: if you’re already running modafinil as your research reference, armodafinil adds essentially nothing new to your understanding. The cognitive enhancement signal in healthy subjects is modest, effect sizes are inconsistent outside sleep-deprived populations, and there’s nothing here that would make a neuropharmacologist sit up. The mechanism is partly contested in the sense that DAT binding alone doesn’t fully explain the wakefulness profile, but that contestation applies equally to the parent racemate. Armodafinil doesn’t give you a better handle on those open questions.

Honestly, the most interesting thing about armodafinil from a research angle is what it can’t explain. If you’re trying to dissect how orexin, histamine, and glutamate downstream effects interact with primary DAT mechanisms, the racemate gives you a natural within-compound control via (S)-modafinil comparison that pure armodafinil doesn’t afford. For translational research into cognitive enhancement or wakefulness circuitry, most investigators reach for modafinil first, or a more novel dopaminergic tool. Armodafinil is competent, mature, and well-characterized. That description is also exactly why it scores where it does.

Novelty: 22
Mechanism promise: 28
In-category differentiation: 38
Evidence quality: 68
Translational signal: 65
Research bench value: 40

Rationale Armodafinil is the isolated R-enantiomer of modafinil, offering a flatter plasma curve and marginally cleaner PK with no new mechanism or indication space; Schedule IV cap of 75 does not bind because raw scores reflect a mature, well-trodden compound class with limited novelty and bench differentiation.

Eugeroic / wakefulness-promoting agent (R-enantiomer)

The (R)-enantiomer of modafinil with extended duration of action and greater wakefulness-promoting potency per milligram.

Abstract

Armodafinil (CAS 112111-43-0; molecular formula C15H15NO2S; molecular weight 273.35) is the (R)-enantiomer of modafinil, marketed under the trade name Nuvigil and approved by the FDA in 2007 for the same indications as racemic modafinil. The (R)-enantiomer carries the majority of the wakefulness-promoting activity of the racemate; the (S)-enantiomer contributes a smaller fraction of the eugeroic effect and metabolizes more rapidly. Pharmacokinetics differ from racemic modafinil principally in elimination: the plasma half-life of armodafinil is 12 to 15 hours, similar to the (R)-enantiomer in racemic modafinil dosing, but absent the early peak from rapid (S)-enantiomer clearance. The result is a flatter plasma concentration curve, with sustained alertness later into the day at lower per-milligram doses. Approved doses are 150 or 250 mg once daily in the morning. Mechanism of action mirrors that of modafinil: weak dopamine transporter binding with downstream orexinergic, histaminergic, and glutamatergic effects. The cognitive enhancement evidence base in healthy individuals overlaps with that of modafinil; the effect sizes are modest and most consistent in sleep-deprived subjects. Schedule IV in the United States. Adverse events parallel those of modafinil; rare DRESS and Stevens-Johnson syndrome cases are documented. Drug interactions through CYP3A4 induction are clinically relevant for hormonal contraception and immunosuppressants.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-017Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Tag: Eugeroic / wakefulness-promoting agent (R-enantiomer)

Armodafinil

Abstract

Read the full monograph